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Abstract
The hedgehog (Hh) signaling pathway regulates many processes of development and tissue
homeostasis. Activation of hedgehog signaling has been reported in about 30% of human cancer
including ovarian cancer. Inhibition of hedgehog signaling has been pursued as an effective strategy
for cancer treatment including an ongoing phase II clinical trial in ovarian cancer. However, the rate
of hedgehog signaling activation in ovarian cancer was reported differently by different groups. To
predict the successful for future clinical trials of hedgehog signaling inhibitors in ovarian cancer, we
assessed hedgehog pathway activation in 34 ovarian epithelial tumor specimens through analyses of
target gene expression by in-situ hybridization, immunohistochemistry, RT-PCR and real-time PCR.
In contrast to previous reports, we only detected a small proportion of ovarian cancers with
hedgehog target gene expression, suggesting that identification of the tumors with activated
hedgehog signaling activation will facilitate chemotherapy with hedgehog signaling inhibitors.
Findings
Ovarian cancer is the most deadly type of gynecological
cancers. Epithelial ovarian cancer is the major ovarian
malignancy consisting of five histological subtypes:
serous, mucinous, endometrioid, transitional and clear
cell [1,2]. Overall, the 5-year relative survival of ovarian
cancer patients is 46%. If diagnosed at the localized stage,
the 5-year survival rate is 93% [3]. The survival of ovarian
carcinoma patients has not improved significantly for
years due to lack of knowledge for molecular mechanisms
underlying ovarian cancer development. Thus, identifying
novel markers for early diagnosis of ovarian cancer can
significantly reduce the mortality of ovarian cancer and
possibly facilitates targeted cancer therapeutics.
The hedgehog (Hh) signaling pathway regulates many
processes of development and tissue homeostasis [4,5]. In
the absence of the ligand Hh, hedgehog receptor (PTCH1
or PTCH2) inhibits smoothened (SMO) signaling. When
Hh binds to PTCH1, SMO is able to signal, eventually
resulting in formation of activated transcriptional factor
Gli (Gli1 and Gli2) molecules and elevated expression of
the target genes (e.g. PTCH1, Gli1, HIP etc). Activation of
hedgehog signaling has been reported in about 30% of
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hedgehog signaling has been pursued as an effective strat-
egy for cancer treatment including an ongoing clinical
trial in solid tumors [7] such as ovarian cancer. Previous
studies showed different results of hedgehog signaling
activation in ovarian cancer. While one study suggests
activation of hedgehog signaling in virtually all tumors
examined using mainly immunohistochemistry [8],
another study indicated a much low rate of hedgehog sig-
naling activation [9]. It appears that a comprehensive
study on ovarian cancer hedgehog signaling is necessary
in order to predict the feasibility of clinical trials of hedge-
hog signaling inhibitors in ovarian cancer. In this study,
we examined hedgehog pathway activation in 34 ovarian
cancer specimens through analyses of target gene expres-
sion by in-situ hybridization, immunohistochemistry, RT-
PCR and real-time PCR (Additional file 1).
Previous studies indicated that sonic hedgehog expression
is elevated in ovarian cancer [1,8-10]. These and other
studies led to a phase II clinical studies in ovarian cancer
using hedgehog inhibitors. We examined three hedgehog
target genes in these specimens: PTCH1, Gli1, HIP1.
Tumors with expression of two hedgehog target genes are
regarded as hedgehog signaling activated tumors. PTCH1
expression was detected in 9 of 34 (~26%). In in-situ
hybridization analysis, most positive staining of PTCH1
was seen in the cancer tissues (Figure 1 indicated by
arrows) not in the adjacent stroma. The antisense probe of
PTCH1 gave positive (blue) signal but the sense probes
did not show staining, indicating the specificity of in-situ
hybridization. Further analysis did not reveal association
between PTCH1 expression and tumor subtypes, stage or
other characteristics (Additional file 2). The result of in-
situ hybridization was confirmed in tumor specimens
with 70% of tissue mass by PCR amplification (Figure 2).
Expression of PTCH1 protein (Figure 3) was further con-
firmed by immunohistochemistry in the specimens with
elevated expression of PTCH1 transcript.
GLI1 and HIP1 expression was detected in 9 of 34 (~26%)
and 7 of 34 (~21%) cancers respectively. Like PTCH1,
most positive staining of GLI1 and HIP1 was shown in
cancer (Fig. 1 indicated by arrows), not in stromal tissues.
Real-time PCR confirmed the results from in-situ hybridi-
zation showed that normal tissues had low or no level of
GLI1 expression whereas tumor tissues had elevated levels
of GLI1 (Figure 2). Like PTCH1, we did not find associa-
tion of Gli1 expression (or HIP1) with any tumor charac-
teristics. The result of RT-PCR shown in Figure 2 was
consistent with result of in-situ hybridization. Further
analysis indicated that PTCH1 co-expressed with GLI1 (p
= 0.0033), but not with HIP1 expression. HIP1 expression
was only detected in 2 specimens which expressed PTCH1
or Gli1, indicating that HIP1 is not highly expressed in
ovarian tissues or is silenced in cancers as reported in
other studies [11,12]. Only 7 out of 34 ovarian cancer
specimens (~21%) have elevated expression of two hedge-
Expression of PTCH1, GLI1 and HIP1 in ovarian cancerFigure 1
Expression of PTCH1, GLI1 and HIP1 in ovarian can-
cer. PTCH1, GLI1 and HIP transcript (blue as positive) was 
detected by in situ hybridization in a well-differentiated 
serous papillary adenocarcinoma (the left panel), and the 
right panel pictures are their controls with respective sense 
probes (Bars indicate 50 μm).
PCR detection of hedgehog signaling in ovarian cancer speci-mensFigur  2
PCR detection of hedgehog signaling in ovarian can-
cer specimens. A. Real-time PCR analysis of GLI1 expres-
sion in ovarian cancer was performed as described in 
Materials and Methods. Gli1 transcript was shown here. B. 
PCR detection of SHH, PTCH1, GLI1, SMO, HIP1 and Su(Fu) 
transcripts in ovarian cancers. GAPDH is the endogenous 
control. Numbers listed indicate specimen number.Page 2 of 5
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hog signaling activation is not very common in ovarian
cancer.
To understand the molecular basis of hedgehog signaling
activation in ovarian cancer specimens, we assessed
expression of hedgehog signaling components in ovarian
cancer. Expression of SHH was found in 11 of 34 (~32%)
ovarian cancers (Additional file 2). By in-situ hybridiza-
tion, we found SHH expression mainly in cancer tissues
(Figure 4 indicated by arrows). PCR also showed that nor-
mal tissues had low or no level of SHH expression, while
tumor tissues had elevated RNA level of SHH (Figure 2).
Further analysis revealed that SHH did not co-express
with hedgehog target genes PTCH1, GLI1 or HIP. SHH
expression was not associated with expression of hedge-
hog target genes (Additional file 2), indicating that SHH
expression alone is not responsible for Hh pathway sign-
aling activation in ovarian cancer.
In addition to SHH, we also detected expression of SMO
and Su(Fu) in 17 ovarian cancers. Although we found
SMO expression in 4 (~24%), and Su(Fu) in 4 (~24%)
tumors respectively. Most tumors with elevated expres-
sion of Gli1 and PTCH1 had no expression of SMO, sug-
gesting that SMO expression was not responsible for
hedgehog signaling activation in ovarian cancer.
The result of in situ hybridization was confirmed by semi-
quantified RT-PCR showing in Figure 2. Expression of
SHH and SMO protein (Figure 3) was also detected by
immunohistochemistry in the specimens with expression
of SHH and SMO by in-situ hybridization and RT-PCR. In
summary of our data, we found only a small proportion
of ovarian cancer specimens with elevated hedgehog sign-
aling activation. Our data also showed that elevated SHH
expression is not always associated with Hh target genes
expression. Based on our data, we caution that clinical tri-
als with hedgehog signaling inhibitors in ovarian cancer
may be successful in selected patient population with ele-
vated Hh target genes.
Using several approaches, we showed that the percentage
of hedgehog signaling activation is low in ovarian cancer.
We only found 20% of tumor specimens with detectable
expression of two hedgehog target genes, as indicated in
real-time PCR and in-situ hybridization analyses. Our data
suggest that it is necessary to identify the right population
of ovarian cancer patients in the clinical trials with hedge-
hog signaling inhibitors. In addition, we found that even
in the tumor with elevated expression of hedgehog target
genes Gli1 and PTCH1, expression of SHH is not necessar-
ily high, suggesting other mechanisms of hedgehog sign-
aling activation in the cancer. The fact that hedgehog
signaling activation is not associated with any particular
subtypes of ovarian cancer suggests that the morphologi-
cal classification of ovarian cancer may not reflect the
Expression of PTCH1, SHH and SMO protein in ovarian can-cerFigure 3
Expression of PTCH1, SHH and SMO protein in 
ovarian cancer. PTCH1, SHH and SMO protein (yellow as 
positive) was detected by immunohistochemistry in a poorly-
differentiated serous papillary adenocarcinoma (left panel), 
and the right panel pictures are controls without primary 
antibody (Bars indicate 50 μm).
Expression of SHH, SMO and Su(Fu) in ovarian cancerFigure 4
Expression of SHH, SMO and Su(Fu) in ovarian can-
cer. SHH, SMO and Su(Fu) transcript (blue as positive) was 
detected by in situ hybridization. The positive stain of SHH, 
SMO was shown in a well-differentiated serous papillary ade-
nocarcinoma and the positive stain of Su(Fu) was shown in a 
poorly-differentiated serous papillary adenocarcinoma (left 
panel), and the right panel pictures are controls of in situ 
hybridization with respective sense probe (the bar indicates 
50 μm).Page 3 of 5
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ests to establish an animal model to study hedgehog sign-
aling-mediated carcinogenesis in ovary.
Different results have been reported on hedgehog signal-
ing activation in ovarian cancer [8,9]. There are several
reasons for this discrepancy. First, different standards have
been used to define Hh signaling activation in ovarian
cancer. One group used immunohistochemistry to detect
expression Hh targets PTCH1 and Gli1 in the tumor spec-
imens [8] whereas we and others assessed the expression
of Hh target genes by several methods: in-situ hybridiza-
tion, real-time PCR and immunohistochemistry.
Although it is possible that our results may under estimate
the frequency of hedgehog signaling, we predict that
screening of Hh signaling activated tumors will signifi-
cantly improve the successful rate of clinical trials using
Hh signaling inhibitors. It is also possible that the
involvement of Hh signaling in human cancers may be
context dependent, occurring in some tissues or cell lines
but not in others. Evidence suggests that Hh signaling may
be involved in maintaining cancer stem cell proliferation
[13,14].
Taken together, our findings suggest that activation of the
Hh pathway is not frequent in ovarian cancer. The fact
that SHH expression is not correlated with Hh target gene
expression suggests that there are other mechanisms
responsible for Hh pathway activation. Our studies pre-
dict that targeted inhibition of the hedgehog pathway may
be only effective in a small percentage of ovarian cancer
patients.
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